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Background: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are functionally the most important
omega-3 polyunsaturated fatty acids (PUFAs). Oral supply of these fatty acids increases their levels in plasma and
cell membranes, often at the expense of the omega-6 PUFAs arachidonic acid (ARA) and linoleic acid. This results in
an altered pattern of lipid mediator production to one which is less pro-inflammatory. We investigated whether
short term intravenous supply of omega-3 PUFAs could change the levels of EPA, DHA, ARA and linoleic acid in
plasma and erythrocytes in patients with hepatic colorectal metastases.
Methods: Twenty patients were randomised to receive a 72 hour infusion of total parenteral nutrition with
(treatment group) or without (control group) omega-3 PUFAs. EPA, DHA, ARA and linoleic acid were measured in
plasma phosphatidylcholine (PC) and erythrocytes at several times points up to the end of infusion and 5 to 12
days (mean 9 days) after stopping the infusion.
Results: The treatment group showed increases in plasma PC EPA and DHA and erythrocyte EPA and decreases in
plasma PC and erythrocyte linoleic acid, with effects most evident late in the infusion period. Plasma PC and
erythrocyte EPA and linoleic acid all returned to baseline levels after the 5–12 day washout. Plasma PC DHA
remained elevated above baseline after washout.
Conclusions: Intravenous supply of omega-3 PUFAs results in a rapid increase of EPA and DHA in plasma PC and
of EPA in erythrocytes. These findings suggest that infusion of omega-3 PUFAs could be used to induce a rapid
effect especially in targeting inflammation.
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Polyunsaturated fatty acids (PUFAs) have important roles
in membrane structure and function, cell signalling and
regulation of gene expression, and as substrates for syn-
thesis of lipid mediators involved in inflammation, im-
munity, coagulation, smooth muscle contraction and
many other physiological responses [1]. The two main
families of PUFAs are the omega-6 and omega-3 families.
The main dietary omega-6 PUFA is linoleic acid [2] and
its derivative, arachidonic acid (ARA), is important with
regard to all of the roles mentioned above [2]. The main
dietary omega-3 PUFA is α-linolenic acid [2]. Its deriva-
tives, eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), are again involved in the roles mentioned
above [3-5], although it is important to note that conver-
sion of α-linolenic acid to EPA, and especially to DHA, ap-
pears to be limited in humans [6]. Omega-6 and omega-3
PUFAs frequently compete with one another for metabol-
ism and often act in an opposing manner to one another
[2-5]. This is especially so for ARA and EPA with regard
to inflammatory processes [7-10]. Hence achieving the
correct “balance” between specific members of the omega-
6 and omega-3 PUFA families is likely to be important for
good health and for improved patient outcomes. Con-
versely a disturbed balance may be associated with poorer
health and poorer patient outcome. Because of the high
dietary abundance of omega-6 PUFAs [11] and the rela-
tively poor abundance of omega-3 PUFAs, omega-6 fatty
acids predominate over omega-3 in blood lipids, blood
cells and most tissues [2-4]. However, increased oral intake
of EPA and DHA results in an increase in their abundance
in blood lipids [12-15], in blood cells [12-15], and in tis-
sues [16-18]. Likewise, intravenous supply of EPA and
DHA increases the content of those fatty acids in blood
lipids [19-22] and in blood cells [23,24].
Patients who undergo major surgery have a risk of infec-
tious complications and these may increase morbidity,
length of hospital stay and mortality. It is possible that the
risk of infection, of further complications and of being un-
able to recover from the complications is increased by a
high status of omega-6 fatty acids and/or a low status of
omega-3 fatty acids, especially EPA and DHA [7,25].
Therefore, providing EPA and DHA in advance of a surgi-
cal insult might reduce the risk of adverse consequences
[25]. Intravenous administration of EPA and DHA, in the
form of a lipid emulsion containing some fish oil, is a
strategy to easily and rapidly increase omega-3 PUFA sup-
ply and status [26-29]. The impact of intravenous fish oil
has been explored in some surgical settings, mainly related
to colorectal cancer resection [25], but not in the context
of removal of liver metastases. The aim of the present
study was to examine the fatty acid composition of plasma
phosphatidylcholine (PC), the major phospholipid in the
circulation, and erythrocytes during and after short termintravenous administration of a lipid emulsion that in-




This study was part of a double blind randomised con-
trolled trial examining the effect of fish oil on human colo-
rectal metastases. Ethical approval was obtained from the
Leicestershire, Northamptonshire and Rutland Research
Ethics Committee (REC number 06/Q2501/16) and ap-
proval for the study was obtained from the Medicines and
Healthcare Products Regulatory Agency (EudraCT num-
ber: 2006-000044-71). The trial is registered at www.
clinicaltrials.gov with identifier NCT00942292. Patients
gave written informed consent.
Patient selection and lipid administration
Patients who had hepatic colorectal metastases larger than
3 cm in diameter were identified from the University Hos-
pitals of Leicester Hepatobiliary Cancer Multi-Disciplinary
Team meetings. Patients where the lesion was deemed
amenable for curative resection were invited to enrol in
the study. To be eligible for inclusion, patients had to have
normal liver function tests and normal plasma lipid con-
centrations. Twenty patients were enrolled in the trial. Pa-
tients were aged 44 to 80 years and there were 9 men and
11 women. Patients received total parenteral nutrition for
72 hr continuously at a rate of 1.5 ml per kilogram body
weight per hr via a peripherally inserted central catheter
and only drank water by mouth. The parenteral nutrition
was in the form of 2000 ml Nutriflex basal® (B Braun,
Melsungen, Germany) compounded with 500 ml Lipidem®
20% (B Braun) in the treatment group or with 500 ml
Lipofundin® MCT 20% (B Braun) in the control group.
Lipidem® (also known as Lipoplus®) is a 50:40:10 (vol/vol/
vol) mix of medium-chain triglycerides, soybean oil and
fish oil; each 100 ml of Lipidem® will typically contain
about 1.25 g EPA plus DHA (0.74 g EPA and 0.51 g
DHA). Lipofundin® MCT is a 50:50 (vol/vol) mix of
medium-chain triglycerides and soybean oil. Median age
(69 years in the control group and 63 years in the treat-
ment groups) and the balance of men and women (5:6 in
the control group and 4:5 in the treatment group) did not
differ between the two groups.
Blood sampling and processing
Blood samples were taken immediately before the infusion
and 1, 3, 6, 20, 44, 68 and 72 hr after starting the infusion.
On finishing the infusion, patients were discharged home
and re-admitted within 2 weeks (5 to 12 days; mean 9
days) to have resection of the liver lesion; at this stage one
further blood sample was taken. Blood was collected into
heparin as anti-coagulant. Blood was centrifuged to obtain
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and stored at −80°C until analysis.
Fatty acid composition of plasma phosphatidylcholine
and erythrocytes
Total lipid was extracted from plasma or erythrocytes
using chloroform/methanol (2:1 vol/vol). PC was sepa-
rated from other plasma lipids by solid phase extraction
on Bond Elut cartridges (Varian, Palo Alto, CA, USA).
Plasma PC and erythrocyte lipids were saponified and
fatty acid methyl esters formed by heating at 50°C for 2
hr in the presence of sulphuric acid containing 2%
methanol. Fatty acid methyl esters were extracted into
hexane and concentrated by evaporation under nitrogen.
Fatty acid methyl esters were separated by gas chroma-
tography on a Hewlett Packard 6890 gas chromatograph
(Hewlett Packard, CA, USA) fitted with a BPX70 column
(SGE Europe, Milton Keynes, Bucks, UK). Running con-
ditions were as described elsewhere [15]. Fatty acids
were identified by comparison of retention times with
those of authentic standards. Data are expressed as per-
centage contribution to the total fatty acid pool. The
main focus of the data shown in this paper is on EPA,
DHA, ARA and linoleic acid.
Statistical analysis
Data are shown as mean + SEM. Data were first analysed
using two-factor ANOVA (factors: time and group) for re-
peated measures. This was followed by analysis of effects
within a group and by pairwise comparisons between
groups as appropriate. Statistical analysis was performed
using GraphPad Prism for windows (GraphPad Software
Inc., CA, USA). Differences were considered significant at
P < 0.05.
Results
The control group (n = 11) received total parenteral nu-
trition for 72 hr with the lipid component being in the
form of a 50:50 (vol/vol) mixture of medium-chain tri-
glycerides and soybean oil. The treatment group (n = 9)
received a 50:40:10 (vol/vol/vol) mixture of medium-
chain triglycerides, soybean oil and fish oil. Blood sam-
ples were taken immediately before infusion and 1, 3, 6,
20, 44, 68 and 72 hr after starting the infusion. A further
sample was collected 5 to 12 days (mean 9 days) after
the end of the infusion period. The fatty acid composi-
tions of plasma PC and erythrocytes were determined.
These did not differ between groups at baseline (i.e.
prior to infusion).
Plasma phosphatidylcholine fatty acids
There was a significant effect of time (P < 0.001) and
group (P < 0.001) and a significant time x group inter-
action (P < 0.001) for plasma PC EPA. Plasma PC EPAshowed a small, but significant, decrease in the control
group (P = 0.004), with the decrease apparent after 20
(P = 0.010 vs baseline), 44 (P = 0.019), 68 (P = 0.002) and
72 (P = 0.003) hr of infusion (Figure 1). Plasma PC EPA
showed a marked and significant increase in the treat-
ment group (P < 0.001), with the increase apparent after
20 (P = 0.066 vs baseline), 44 (P < 0.001), 68 (P < 0.001)
and 72 (P < 0.001) hr of infusion (Figure 1). Plasma PC
EPA was higher in the treatment group than in the con-
trol group at 20, 44, 68 and 72 hr (all P < 0.001). Plasma
PC EPA returned to baseline values in both control and
treatment groups after the 5 to 12 day washout period
(Figure 1).
There was a significant effect of time (P < 0.001) and a
significant time x group interaction (P < 0.001) for
plasma PC DHA. Plasma PC DHA did not change sig-
nificantly in the control group (P > 0.05; Figure 1).
Plasma PC DHA increased in the treatment group (P <
0.001), with the increase apparent at 44 (P = 0.031 vs
baseline), 68 (P = 0.008) and 72 (P = 0.011) hr (Figure 1).
Plasma PC DHA was higher in the treatment group than
in the control group at 68 (P = 0.007) and 72 (P = 0.067)
hr. Plasma PC DHA remained elevated above baseline
levels (P = 0.050) in the treatment group after the 5 to
12 day washout period (Figure 1).
There was a significant effect of time (P < 0.001) and a
strong trend toward a significant time x group inter-
action (P = 0.062) for plasma PC ARA. Plasma PC ARA
tended to decrease in the both groups (Figure 1). How-
ever, there were no significant differences from baseline
in either group and there were no differences between
groups at any timepoint.
There was a significant effect of time (P < 0.001) and a
significant time x group interaction (P < 0.001) for
plasma PC linoleic acid. Plasma PC linoleic acid did not
change in the control group (P > 0.05; Figure 1). Plasma
PC linoleic acid decreased in the treatment group (P <
0.001). In the treatment group plasma PC linoleic acid
was lower than baseline at 44 (P = 0.019), 68 (P = 0.008)
and 72 (P = 0.004) hr. Plasma PC linoleic acid differed
between the control and treatment groups at 68 (P =
0.038) and 72 (P = 0.009) hr. Plasma PC linoleic acid
returned to baseline values after the 5 to 12 day washout
period (Figure 1).
As a result of these changes in EPA, DHA and linoleic
acid content of plasma PC the omega-6 to omega-3 ratio
was significantly decreased late in the infusion period in
the treatment group (at 20, 44, 68 and 72 hr). There was
no difference in the proportion of any other fatty acid in
plasma PC between the two groups or over time.
Erythrocyte fatty acids
There was a strong trend toward a significant time x group
























































































































Figure 1 Plasma PC eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid and linoleic acid before (baseline),
during (1 hr to 72 hr) and 5–12 days after stopping infusion of a mixture of medium-chain triglycerides and soybean oil (control: filled
circles joined by solid lines) or medium-chain triglycerides, soybean oil and fish oil (fish oil: filled squares joined by dotted lines). Data
are mean ± SEM. *indicates significantly different from baseline value in the same group. †indicates significantly different from control group at
the same timepoint. 5–12 days w/o indicates the samples collected 5 to 12 days after stopping the infusions.
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(Figure 2), but increased in the treatment group late in
the infusion period (P < 0.005) (Figure 2). However, fur-
ther analysis did not show any significant differences
compared to baseline erythrocyte EPA or compared
with the control group. Erythrocyte EPA returned to
baseline values in the treatment group after the 5 to 12
day washout period (Figure 2). Erythrocyte DHA and
ARA did not change significantly in either group and
the groups did not differ at any timepoint (Figure 2).
There was a significant effect of time (P = 0.011) and a
significant time x group interaction (P = 0.012) for
erythrocyte linoleic acid. Erythrocyte linoleic acid did
not change in the control group but decreased in the
treatment group late in the infusion period before
returning to baseline levels at the 5 to 12 day washout
(Figure 2). However, further analysis did not show any sig-
nificant differences compared to baseline erythrocyte lino-
leic acid or compared with the control group. There was
no difference in the proportion of any other fatty acid in
erythrocytes between the two groups or over time.
Discussion
This current study shows that intravenous infusion of
omega-3 PUFAs in the form of Lipidem® (B. Braun,
Melsungen, Germany) induces a fairly rapid and marked
increase in EPA and DHA in plasma PC and a smallincrease of EPA in erythrocytes. Amongst these changes,
the elevation of EPA in plasma PC occurred the earliest.
Interestingly in the control group not receiving fish oil-
type omega-3 PUFAs there was a small decline in
plasma PC EPA. The effect of the infusion of omega-3
PUFAs on plasma PC and erythrocyte EPA was reversed
when the infusion was stopped. In contrast, elevated
DHA was retained in plasma PC beyond the end of the
infusion period. The retention of DHA in plasma PC
was more marked in some individuals that others. Over-
all these data indicate that infused omega-3 PUFAs, es-
pecially EPA, are rapidly incorporated into plasma PC
and also into erythrocytes and that turnover of EPA and
DHA in plasma PC is different so that there is retention
of DHA after supply is terminated even when EPA has
returned to its starting level. Thus, this study provides
further evidence that EPA and DHA may be handled dif-
ferently in the body. The preferential retention of DHA
has been demonstrated in plasma phospholipids [13],
platelets [30], white blood cells [13] and erythrocytes
[12,31] after oral dosing of omega-3 PUFAs. These ob-
servations might indicate a special functional signifi-
cance or importance of DHA over EPA
The rapid appearance of EPA and DHA with intraven-
ous infusion is an advantage over oral supply where ap-
pearance of these fatty acids is slower [12-15,32]. This is










































































































Figure 2 Erythrocyte eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid and linoleic acid before (baseline),
during (1 hr to 72 hr) and 5–12 days after stopping infusion of a mixture of medium-chain triglycerides and soybean oil (control: filled
circles joined by solid lines) or medium-chain triglycerides, soybean oil and fish oil (fish oil: filled squares joined by dotted lines). Data
are mean ± SEM. There were no significant pairwise differences between timepoints within a group or between groups at any timepoint. 5–12
days w/o indicates the samples collected 5 to 12 days after stopping the infusions.
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before the fatty acids can be incorporated into plasma
lipids and of further processing before they can be incor-
porated into cellular lipids. These processes all take time
and depend on other factors such as the fat content and
macronutrient composition of the meal. In contrast,
intravenous infusion provides the fatty acids directly into
the bloodstream introducing them into blood lipids, like
PC, and directly exposing cells very quickly. A second
aspect of intravenous infusion that will favour incorpor-
ation of EPA and DHA is the dose that can be adminis-
tered. Studies of oral dosing typically use 1 to 4 g EPA +
DHA per day, although higher doses have been used in
some studies. In contrast, intravenous administration
can easily provide more than 10 g of EPA +DHA on a
daily basis. The higher dose will promote quicker incorp-
oration and also a higher level of incorporation than is
possible with oral supply. It is important to note that this
high level of intravenous omega-3 PUFAs was well toler-
ated in all patients and there were no adverse reactions
shown by study participants. Again this is an advantage
over oral supply where moderate to high doses of fish oil
can be associated with adverse gastrointestinal reactions.
The increase in EPA and DHA, which was mirrored
by a decrease in the omega-6 fatty acid linoleic acid,
resulting in decrease in the omega-6 to omega-3 PUFAratio could be functionally important especially with re-
gard to inflammation [7-10] and perhaps also immune
function [33] and blood coagulation [34]. The infusion
of EPA +DHA promotes an anti-inflammatory and anti-
coagulatory environment that would be an advantage in
many patient groups including acute severe pancreatitis,
sepsis, head trauma and even in advance of major
gastrointestinal or hepatic surgery. In the current study
the functional implications of the fatty acid changes de-
scribed were not investigated.
Erythrocytes from patients receiving intravenous fish oil
did not show an elevation of DHA, despite the small ele-
vation of EPA. This suggests a slower rate of incorporation
of DHA than EPA into erythrocytes and that the period of
infusion (72 hr) was insufficient for net DHA incorpor-
ation to occur. Browning et al. [15] demonstrated slower
appearance of DHA than EPA into erythrocytes of healthy
subjects consuming oral supplements containing EPA and
DHA. Once again these observations indicate a slower
turnover of DHA than EPA in cells.
The control group received a mixture of soybean oil
and medium-chain triglycerides. This mix is fairly rich
in linoleic acid, although less so than traditional soybean
oil lipid emulsions [35]. One interesting observation is
that plasma PC EPA decreased slightly but significantly
in the control group. Given the role of EPA in limiting
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seen in the control group suggests an undesirable effect
of infusing lipid that does not contain preformed EPA.
In the clinical setting, the overall aim of the infusion
protocol used here would be to enrich cells and tissues
with biologically active omega-3 PUFAs in order to slow
or reduce tumour growth and to promote a favourable re-
sponse to a subsequent insult such surgery. Such a
favourable response might involve prevention of excessive
inflammation and reducing the likelihood of immune par-
alysis. Here, erythrocyte fatty acids were measured as a
surrogate for those in tissue. At the end of the infusion
period EPA had increased in erythrocytes of those patients
receiving the intravenous fish oil. However, the infusion
period was stopped some days before surgery and this
resulted in a reversal of the infusion-induced fatty acid
composition change in erythrocytes. This may also have
occurred in tissues including the liver. It will be important
in future studies to prolong the infusion period up to the
time of surgery, in order to maximise the likelihood of
establishing a beneficial impact of omega-3 fatty acids on
the response to surgery, and to sample liver tissue in order
to confirm that its fatty acid composition is modified. Fur-
thermore, it will be important to link changes in plasma,
blood cell and tissue fatty acid composition to biological
effects such as the concentrations of lipid mediators and
cytokines and to clinical outcomes.
Conclusions
Intravenous supply of omega-3 PUFAs results in a rapid
increase of EPA and DHA in plasma PC and of EPA in
erythrocytes, suggesting that infusion of omega-3 PUFAs
could be used to induce a rapid effect especially in
targeting inflammation.
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